12 Best Up and Coming Stocks to Buy According to Wall Street Analysts

Page 11 of 11

1. Janux Therapeutics Inc. (NASDAQ:JANX)

Average Upside Potential as of March 21: 162.90%

Number of Hedge Fund Holders: 54

Janux Therapeutics Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company that develops immunotherapies for cancer. Using its TRACTr and TRACIr platforms, it’s advancing candidates like JANX007 and JANX008 for various solid tumors. It also collaborates with Merck Sharp & Dohme Corp. to further develop its TRACTr technology.

The company is concentrating its efforts on its TRACTr therapy, specifically JANX007, which targets prostate-specific membrane antigen (PSMA) for prostate cancer treatment. Recent Phase 1 clinical trial data for JANX007 in metastatic castration-resistant prostate cancer (mCRPC) showed promising results. 100% of patients achieved PSA50 declines, 63% achieved PSA90 declines, and 50% demonstrated anti-tumor activity. The company plans to provide updates on JANX007 data in 2025 and is continuing patient enrollment in the ongoing Phase 1 trial.

On March 1, Scotiabank reduced its price target for the company from $62 to $41, while maintaining a Sector Perform rating. This adjustment reflects a more conservative outlook on JANX007’s potential, despite promising dose-escalation results from the ongoing Phase 1 trial. The firm believes that Janux Therapeutics Inc. (NASDAQ:JANX) has not yet met all the benchmarks necessary to establish a competitive advantage and attract a pharmaceutical acquisition.

While we acknowledge the growth potential of Janux Therapeutics Inc. (NASDAQ:JANX), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JANX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 11 of 11